share_log

大行评级|大华继显:下调阿里健康目标价至4港元 维持“买入”评级

Big Bank Rating | Dahua Jixian: Lowering Ali Health's Target Price to HK$4 to Maintain “Buy” Rating

Gelonghui Finance ·  Apr 7 22:22

Dahua Jixian published a report. Alibaba Health's revenue for the 2024 fiscal year is expected to drop 5% year-on-year, adjusted profit will increase by 30% year-on-year, and the revenue and profit targets for fiscal year 2025 are 15% and 70% year-on-year growth, respectively. As business expansion was slower than expected, the bank lowered Ali Health's revenue growth forecast for the 2024 and 2025 fiscal years from 14% and 21% to -5% and 15%, respectively, but with the synergy between steady demand for healthcare products and Ali Mama's marketing business, it remains optimistic about its long-term growth prospects. Dahua Jixian maintained Ali Health's “buy” rating, and the target price was lowered from HK$6 to HK$4.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment